For patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, prolongs progression-free survival and improves response compared with standard regimens.
The Fiji TimesWhat s happening today! - The Fiji Times fijitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fijitimes.com Daily Mail and Mail on Sunday newspapers.
MIDDLEFIELD CANADIAN INCOME PCC
a cell of the Company
For the year ended 31 December 2020
55
59
60
67
68
Equity of the Fund
70
71
87
90
91
Middlefield Canadian Income Trust
Targeting high levels of stable income and capital growth, this Trust is primarily focused on Canada’s highest quality large cap businesses. This Trust is run by a private and independent asset manager located in Toronto, Canada and has delivered consistent and material income for UK investors for more than a decade.
Objective
The Fund seeks to provide shareholders with high levels of dividend income as well as capital growth over the long term.
Reasons to Buy
Unique
Share this article
DRESDEN, Germany, March 2, 2021 /PRNewswire/
GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced the publication of clinical data obtained from the ongoing Phase I study of their rapidly switchable UniCAR platform lead asset, UniCAR-T-CD123, in relapsed/refractory acute myeloid leukemia (rrAML), in the journal Blood .
The interim data of UniCAR-T-CD123 in rrAML, published online ahead of print as a letter in
Blood (Wermke et al. 2021, https://doi.org/10.1182/blood.2020009759), demonstrate that UniCAR-T-CD123 in rrAML is well-tolerated with rapid recovery of hematopoiesis and encouraging early efficacy. The Blood publication nicely underpins the clinical advantages of our rapidly switchable UniCAR platform, which have also been recently presented at the 3